Nation & World

'Pharma Bro' Shkreli gets 7 years for defrauding investors

FILE PHOTO: Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York, U.S., June 26, 2017.  REUTERS/Lucas Jackson/File Photo
FILE PHOTO: Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York, U.S., June 26, 2017. REUTERS/Lucas Jackson/File Photo

NEW YORK — Martin Shkreli, the former drug company executive who made headlines by jacking up the price of a lifesaving drug before he was found guilty of defrauding investors, was sentenced to 7 years and a $75,000 fine on Friday.

The sentence from U.S. District Judge Kiyo Matsumoto in federal court in Brooklyn, New York, was shorter than the 15 years asked for by prosecutors but much longer than the 12 to 18 months Shkreli’s lawyers had sought.

Shkreli’s lawyer Benjamin Brafman told the judge before the sentencing that Shkreli, 34, suffered from depression and an anxiety disorder and was a “somewhat broken” person, whom the government wanted to “throw away.”

Assistant U.S. Attorney Jacquelyn Kasulis had said a 15 year sentence was justified in part because Shkreli’s crimes were not an “isolated lapse in judgment,” but a pattern of conduct including separate frauds for his two hedge funds and for his drug company Retrophin Inc.

The Brooklyn-born entrepreneur became known as the “Pharma Bro” in September 2015 after founding Turing Pharmaceuticals, buying the anti-parasitic drug Daraprim and raising its price by 5,000 percent to $750 per pill. Shkreli was indicted for the unrelated securities fraud charges in December 2015.

At the hearing, Shkreli had choked up as he said he had learned from his mistakes.

“There is no conspiracy to take down Martin Shkreli. I took down Martin Shkreli with my disgraceful and shameful actions,” he said.

A jury in August found Shkreli guilty of defrauding investors in two hedge funds he ran, MSMB Capital and MSMB Healthcare, by sending them fake account statements and concealing huge losses. He was also convicted of scheming to prop up the stock price of Retrophin, the drug company he founded in 2011.

ARTICLE CONTINUES BELOW ADVERTISEMENT

The $75,000 fine comes on top of $7.36 million in forfeiture Shkreli had already been ordered to pay following his conviction.

Brafman, noting that he was old enough to be Shkreli’s father, said his client had not always been easy to work with.

“There are times when I want to hug him and hold him and comfort him and there are times when I want to punch him in the face,” Brafman said.

Kasulis said Brafman was trying to portray Shkreli as “a child.”

“Mr. Shkreli is about to turn 35 years old,” she said “ He is a man who needs to take responsibility for his actions.”

Shkreli has been in jail since September, when Matsumoto revoked his bail after he offered his social media followers $5,000 if they could bring him a hair from former U.S. presidential candidate Hillary Clinton.

(Reporting By Brendan Pierson in New York; Editing by Meredith Mazzilli and Chizu Nomiyama)

Give us feedback

We value your trust and work hard to provide fair, accurate coverage. If you have found an error or omission in our reporting, tell us here.

Or if you have a story idea we should look into? Tell us here.

CONTINUE READING

MORE Nation & World ARTICLES TO READ NEXT ...

Chinese investors are pumping money into U.S. drug start-ups as Beijing seeks to become a global leader in new medicines, adding to a flood of cash flowing to groundbreaking health businesses.Venture-capital funds based in China p ...

Thousands of family-friendly apps from the Google Play Store potentially are violating federal law, according to a new large-scale study from North American and European universities and organizations.The research, recently publis ...

Give us feedback

We value your trust and work hard to provide fair, accurate coverage. If you have found an error or omission in our reporting, tell us here.

Or if you have a story idea we should look into? Tell us here.